🔗 Share this article

An underground economy for unlicensed weight-loss medications is being driven by TikTok fitness influencers and sellers on messaging platforms, according to new investigations.

Experimental Drug Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to message these accounts directly for supplier links, while also receiving promotional offers.

Active Trade on Messaging Platforms

Separately, a robust market exists on messaging services, where communities with thousands of members share comparison images, administration instructions and assertions of next-day British shipping. Vendors market the substance there before redirecting buyers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an investigational injectable created by US drugmaker Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Medical Experts Express Worries

However, doctors and pharmacists have cautions that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering substances of uncertain source.

Several experts said the demand for the experimental drug could be connected to the increasing cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on TikTok or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the British medical regulations.

Several influencers attempt to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still breach pharmaceutical, marketing, and consumer regulations, risking fines, prosecution or imprisonment.

Platform Reaction and Material Removal

Based on the social media company, the platform has removed problematic material and banned related keywords and search suggestions. The organization said it was committed to maintaining the service safe and investing in enhancing compliance measures.

Digital Trading Operations

Research also found communities with up to 9,000 participants selling retatrutide using the platform's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, populated with images of weight loss, positive reviews and detailed guides for preparing or injecting at home.

After minutes of joining one group, a seller posted contact information, where most transactions occur. The vendor sent an instruction manual and guaranteed delivery within two days. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one inquired about weight, medical conditions or previous experience.

Item Information and Costs

Within these groups, messages display dark colored parcels with postal service labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at residence with sterile water, or ready-to-use injectors typically sold at 160 pounds for 20mg. When questioned how long a pen should be used, sellers give contradictory responses varying between a few weeks to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for the messaging service stated it regularly moderated dangerous content on its platform including content that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are injecting materials they cannot confirm. Even if the research behind retatrutide is sound, these online products may not include what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in demand to recent price rises for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are turning to social media. But fake treatments are extremely risky. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her staff has previously seen patients harmed by personal administration from unverified sources. “We understand the frustration, but purchasing from Telegram or communication platforms is gambling with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Position

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this point no one can sell [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company investigational substance not yet authorized … may subject users to possibly serious health risks”.